326 related articles for article (PubMed ID: 35508466)
1. Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.
Ng CKY; Dazert E; Boldanova T; Coto-Llerena M; Nuciforo S; Ercan C; Suslov A; Meier MA; Bock T; Schmidt A; Ketterer S; Wang X; Wieland S; Matter MS; Colombi M; Piscuoglio S; Terracciano LM; Hall MN; Heim MH
Nat Commun; 2022 May; 13(1):2436. PubMed ID: 35508466
[TBL] [Abstract][Full Text] [Related]
2. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma.
Gao Q; Zhu H; Dong L; Shi W; Chen R; Song Z; Huang C; Li J; Dong X; Zhou Y; Liu Q; Ma L; Wang X; Zhou J; Liu Y; Boja E; Robles AI; Ma W; Wang P; Li Y; Ding L; Wen B; Zhang B; Rodriguez H; Gao D; Zhou H; Fan J
Cell; 2019 Oct; 179(2):561-577.e22. PubMed ID: 31585088
[TBL] [Abstract][Full Text] [Related]
3. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
4. Integrated proteogenomic characterization reveals an imbalanced hepatocellular carcinoma microenvironment after incomplete radiofrequency ablation.
Shi ZR; Duan YX; Cui F; Wu ZJ; Li MP; Song PP; Peng QL; Ye WT; Yin KL; Kang MQ; Yu YX; Yang J; Tang W; Liao R
J Exp Clin Cancer Res; 2023 May; 42(1):133. PubMed ID: 37231509
[TBL] [Abstract][Full Text] [Related]
5. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
6. Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma.
Liao H; Du J; Wang H; Lan T; Peng J; Wu Z; Yuan K; Zeng Y
J Hematol Oncol; 2021 Dec; 14(1):205. PubMed ID: 34895304
[TBL] [Abstract][Full Text] [Related]
7. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
[TBL] [Abstract][Full Text] [Related]
8. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Lachenmayer A; Alsinet C; Savic R; Cabellos L; Toffanin S; Hoshida Y; Villanueva A; Minguez B; Newell P; Tsai HW; Barretina J; Thung S; Ward SC; Bruix J; Mazzaferro V; Schwartz M; Friedman SL; Llovet JM
Clin Cancer Res; 2012 Sep; 18(18):4997-5007. PubMed ID: 22811581
[TBL] [Abstract][Full Text] [Related]
9. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic STRAP Supports Hepatocellular Carcinoma Growth by Enhancing Wnt/β-Catenin Signaling.
Wang W; Li S; Liu P; Sideras K; van de Werken HJG; van der Heide M; Cao W; Lavrijsen M; Peppelenbosch MP; Bruno M; Pan Q; Smits R
Mol Cancer Res; 2019 Feb; 17(2):521-531. PubMed ID: 30257989
[TBL] [Abstract][Full Text] [Related]
11. β-Catenin signaling in hepatocellular carcinoma.
Xu C; Xu Z; Zhang Y; Evert M; Calvisi DF; Chen X
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166233
[TBL] [Abstract][Full Text] [Related]
12. Proteomic analysis and translational perspective of hepatocellular carcinoma: Identification of diagnostic protein biomarkers by an onco-proteogenomics approach.
Chiou SH; Lee KT
Kaohsiung J Med Sci; 2016 Nov; 32(11):535-544. PubMed ID: 27847095
[TBL] [Abstract][Full Text] [Related]
13. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
14. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Boyault S; Rickman DS; de Reyniès A; Balabaud C; Rebouissou S; Jeannot E; Hérault A; Saric J; Belghiti J; Franco D; Bioulac-Sage P; Laurent-Puig P; Zucman-Rossi J
Hepatology; 2007 Jan; 45(1):42-52. PubMed ID: 17187432
[TBL] [Abstract][Full Text] [Related]
15. CTNNB1 mutations and beta-catenin protein accumulation in human hepatocellular carcinomas associated with high exposure to aflatoxin B1.
Devereux TR; Stern MC; Flake GP; Yu MC; Zhang ZQ; London SJ; Taylor JA
Mol Carcinog; 2001 Jun; 31(2):68-73. PubMed ID: 11429783
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography.
Gougelet A; Sartor C; Senni N; Calderaro J; Fartoux L; Lequoy M; Wendum D; Talbot JN; Prignon A; Chalaye J; Imbeaud S; Zucman-Rossi J; Tordjmann T; Godard C; Bossard P; Rosmorduc O; Amaddeo G; Colnot S
Gastroenterology; 2019 Sep; 157(3):807-822. PubMed ID: 31194980
[TBL] [Abstract][Full Text] [Related]
17. Alterations of Wnt/β-catenin signaling pathway in hepatocellular carcinomas associated with hepatitis C virus.
Rogacki K; Kasprzak A; Stępiński A
Pol J Pathol; 2015 Mar; 66(1):9-21. PubMed ID: 26017875
[TBL] [Abstract][Full Text] [Related]
18. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes.
Bidkhori G; Benfeitas R; Klevstig M; Zhang C; Nielsen J; Uhlen M; Boren J; Mardinoglu A
Proc Natl Acad Sci U S A; 2018 Dec; 115(50):E11874-E11883. PubMed ID: 30482855
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
20. Berberine Represses
Vishnoi K; Ke R; Saini KS; Viswakarma N; Nair RS; Das S; Chen Z; Rana A; Rana B
Mol Pharmacol; 2021 Jan; 99(1):1-16. PubMed ID: 33130557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
